Koriyama, Fukushima
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Phase
3Span
217 weeksSponsor
Karuna TherapeuticsKoriyama, Fukushima
Recruiting
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
Phase
2Span
143 weeksSponsor
Kyowa Kirin Co., Ltd.Koriyama, Fukushima
Recruiting
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)
Phase
3Span
283 weeksSponsor
UCB Biopharma SRLKoriyama
Recruiting
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Phase
3Span
178 weeksSponsor
SanofiKoriyama, Fukushima
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Phase
3Span
108 weeksSponsor
Karuna TherapeuticsKoriyama, Fukushima
Recruiting
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Phase
3Span
222 weeksSponsor
SanofiKoriyama, Fukushima
Recruiting
1-7 of 7